The Company’s 2024 report showcases a year of strategic realignment, technological advancement, and enhanced corporate governance - positioning BGLC for sustainable long-term growth.

BioNexus Gene Lab没有发行零碎股份，而是根据反向拆股前十个交易日的成交量加权平均价格 (VWAP)向股东提供现金支付。公司已更正此前报告的现金支付价格，确保股东获得适当价值的零碎股份补偿。

Investing.com — BioNexus Gene Lab Corp (NASDAQ: BGLC )，一家市值447万美元的医疗实验室服务提供商，已宣布将从周一开盘起实施普通股反向拆股。此举旨在解决公司在纳斯达克规则下的最低竞价价格不足问题。根据 InvestingPro 数据，BGLC股价在过去一年下跌超过57%，目前交易价格为0.25美元。

KUALA LUMPUR, Malaysia, April 15, 2025 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (Nasdaq: BGLC) (“BioNexus” or the “Company”), a diversified biotechnology and specialty materials group ...

About BioNexus Gene Lab Corp. BioNexus Gene Lab Corp. (Nasdaq: BGLC) is a Wyoming-incorporated, Nasdaq-listed company with operating subsidiaries in Malaysia focused on molecular diagnostics and ...

KUALA LUMPUR, Malaysia, April 15, 2025 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (Nasdaq: BGLC) ("BioNexus” or the "Company”), a diversified biotechnology and specialty materials group headquartered ...

BioNexus Gene Lab Corporation (BGLC) shares tumbled to a 52-week low, touching down at $0.22, with a price-to-book ratio of just... ByInvesting.com • Dec 20, 2024 BGLC stock touches 52-week low ...

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> ...

Enhance your stock picks with dividend metrics like per-share dividends, yield, frequency, payout ratios, and more.